Company description

BCYC, or Bicycle Therapeutics, is a cutting-edge clinical-stage biopharmaceutical company that is focused on developing and commercializing a new class of medicines based on its proprietary bicyclic peptide (Bicycle) product platform. The company's goal is to revolutionize the treatment of serious diseases, such as cancer and other genetic or cardiometabolic disorders, by harnessing the power of its innovative technology. Bicycle Therapeutics has a robust pipeline with multiple candidates in various stages of development, and its lead product candidate, BT1718, is currently being evaluated in a Phase I/IIa clinical trial for the treatment of advanced solid tumors. Additionally, the company has strong partnerships with world-renowned pharmaceutical companies, demonstrating the potential and value of its technology. With a highly experienced team and a commitment to innovation and scientific excellence, BCYC is poised to make a significant impact in the field of therapeutics, ultimately improving the lives of patients.